Recorded Presentation from the NCCN Pharmacy Updates: Introduction to the NCCN Guidelines® for Myeloproliferative Neoplasms and a Comprehensive Review of the Use of JAK2 Inhibitors
Join Stephen J.
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Patient Case Studies and Panel Discussion: Leukemia and Myeloproliferative Neoplasms
Although advances in treatment options for patients with hematologic malignancies are encouraging, the rapidly changing scientific and clinical environment represents a daunting challenge for practitioners.
Category
  • Leukemia
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Prognostic Significance of Mutations in Myeloproliferative Neoplasms
The diagnosis and management of patients with myeloproliferative neoplasms (MPN) has evolved since the identification of “driver” mutations (JAK2, CALR, and MPL mutations).
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation